EA201591758A1 - Подкожное введение adamts13 - Google Patents

Подкожное введение adamts13

Info

Publication number
EA201591758A1
EA201591758A1 EA201591758A EA201591758A EA201591758A1 EA 201591758 A1 EA201591758 A1 EA 201591758A1 EA 201591758 A EA201591758 A EA 201591758A EA 201591758 A EA201591758 A EA 201591758A EA 201591758 A1 EA201591758 A1 EA 201591758A1
Authority
EA
Eurasian Patent Office
Prior art keywords
adamts13
introduction
sub
subcutaneous administration
formulations
Prior art date
Application number
EA201591758A
Other languages
English (en)
Other versions
EA201591758A8 (ru
EA034546B1 (ru
Inventor
Александра Натали Шивиц
Вернер Хелльригль
Барбара Плаймауэр
Ханспетер Роттенштайнер
Ева-Мария Мухич
Original Assignee
Баксалта Инкорпорейтед
Баксалта Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Баксалта Инкорпорейтед, Баксалта Гмбх filed Critical Баксалта Инкорпорейтед
Publication of EA201591758A1 publication Critical patent/EA201591758A1/ru
Publication of EA201591758A8 publication Critical patent/EA201591758A8/ru
Publication of EA034546B1 publication Critical patent/EA034546B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Изобретение относится к способам подкожного введения составов ADAMTS13 для лечения заболевания или состояния, ассоциированного с дисфункцией ADAMTS13 и ФВ. Кроме того, в настоящем документе представлены доказательства неожиданно высокой биодоступности составов ADAMTS13 для подкожного введения.
EA201591758A 2013-03-15 2014-03-13 Способ лечения заболевания, связанного с расстройством системы свертывания крови и способ лечения эпизода кровотечения у млекопитающего EA034546B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361794659P 2013-03-15 2013-03-15
PCT/US2014/026747 WO2014151968A1 (en) 2013-03-15 2014-03-13 Subcutaneous administration of adamts13

Publications (3)

Publication Number Publication Date
EA201591758A1 true EA201591758A1 (ru) 2016-03-31
EA201591758A8 EA201591758A8 (ru) 2017-03-31
EA034546B1 EA034546B1 (ru) 2020-02-19

Family

ID=50549463

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201992832A EA201992832A1 (ru) 2013-03-15 2014-03-13 Подкожное введение adamts13
EA201591758A EA034546B1 (ru) 2013-03-15 2014-03-13 Способ лечения заболевания, связанного с расстройством системы свертывания крови и способ лечения эпизода кровотечения у млекопитающего

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201992832A EA201992832A1 (ru) 2013-03-15 2014-03-13 Подкожное введение adamts13

Country Status (19)

Country Link
US (4) US9611467B2 (ru)
EP (2) EP3960196A1 (ru)
JP (4) JP6484216B2 (ru)
KR (5) KR102218489B1 (ru)
CN (2) CN114259558A (ru)
AU (5) AU2013203062C1 (ru)
BR (1) BR112015023542A8 (ru)
CA (1) CA2905058A1 (ru)
DK (1) DK2968483T3 (ru)
EA (2) EA201992832A1 (ru)
ES (1) ES2906550T3 (ru)
HK (1) HK1220131A1 (ru)
IL (3) IL241305B (ru)
MX (2) MX2015012783A (ru)
PL (1) PL2968483T3 (ru)
PT (1) PT2968483T (ru)
SG (3) SG11201507271QA (ru)
TW (4) TWI740207B (ru)
WO (1) WO2014151968A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203062C1 (en) 2013-03-15 2018-06-28 Takeda Pharmaceutical Company Limited Subcutaneous administration of adamts13
GB201510870D0 (en) * 2015-05-26 2015-08-05 Baxalta Inc And Katholieke Universiteit Leuven And Baxalta Gmbh Treatment of infarction
MX2019001255A (es) 2016-08-04 2019-05-20 Baxalta Inc Uso de una desintegrina y metaloproteinasa con motivo tipo 1 de trombospondina, miembro-13 (adamts13) para tratar, mejorar y/o prevenir crisis vaso-oclusiva en enfermedad de celulas falciformes, lesion pulmonar aguda y/o sindrome de insuficiencia respiratoria aguda.
WO2020214033A1 (en) * 2019-04-17 2020-10-22 Erasmus University Medical Center Rotterdam Papain-like cysteine peptidase medicaments and uses thereof
KR20230005192A (ko) 2020-04-02 2023-01-09 다케다 야쿠힌 고교 가부시키가이샤 Adamts13 변이체, 조성물 및 그의 용도
WO2021234458A1 (en) 2020-05-22 2021-11-25 Takeda Pharmaceutical Company Limited Adamts13 compositions and methods for treating and diagnosing complications of coronavirus disease
US20230405096A1 (en) * 2020-11-18 2023-12-21 Green Cross Corporation Adamts13 variant having increased escaping rate or activity against autoantibody
GB202102208D0 (en) * 2021-02-17 2021-03-31 Univ Manchester Adamts13 variant
WO2024151093A1 (ko) * 2023-01-11 2024-07-18 주식회사 녹십자 혈전성 질환의 예방 또는 치료를 위한 신규한 액상 제형물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL113010A0 (en) 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
US6926894B2 (en) 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
WO2003016492A2 (en) * 2001-08-16 2003-02-27 The Regents Of The University Of Michigan Adamts13 genes and proteins and variants, and uses thereof
US7763430B2 (en) * 2003-04-22 2010-07-27 Baxter International Inc. Diagnostic assay for anti-von Willebrand Factor cleaving protease (ADAMTS13) antibodies
ES2382104T3 (es) 2005-06-17 2012-06-05 Baxter International Inc. Composiciones con actividad trombolítica que comprenden ADAMTS13
JP2009539757A (ja) * 2006-06-16 2009-11-19 バクスター・インターナショナル・インコーポレイテッド 血栓溶解活性を有するａｄａｍｔｓ１３含有組成物
EP2288377A1 (en) 2008-05-12 2011-03-02 Immune Disease Institute Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
AU2010284977A1 (en) * 2009-08-20 2012-03-29 Csl Behring Gmbh Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
JP5819303B2 (ja) * 2009-09-21 2015-11-24 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 安定化された液体および凍結乾燥ａｄａｍｔｓ１３製剤
TWI670073B (zh) 2010-07-08 2019-09-01 美商巴克斯歐塔公司 在細胞培養物中生產重組高分子量ｖＷＦ的方法
AU2013203062C1 (en) 2013-03-15 2018-06-28 Takeda Pharmaceutical Company Limited Subcutaneous administration of adamts13

Also Published As

Publication number Publication date
WO2014151968A1 (en) 2014-09-25
TWI690326B (zh) 2020-04-11
AU2013203062C1 (en) 2018-06-28
IL241305A0 (en) 2015-11-30
US11779635B2 (en) 2023-10-10
KR102513872B1 (ko) 2023-03-27
US20200101144A1 (en) 2020-04-02
IL290486A (en) 2022-04-01
TW202017591A (zh) 2020-05-16
MX2021002513A (es) 2021-04-28
DK2968483T3 (da) 2022-02-14
JP6484216B2 (ja) 2019-03-13
AU2020202738A1 (en) 2020-05-14
IL290486B2 (en) 2023-08-01
TW201513881A (zh) 2015-04-16
TWI740207B (zh) 2021-09-21
EA201992832A1 (ru) 2020-05-31
NZ749570A (en) 2020-11-27
US20140271611A1 (en) 2014-09-18
US9611467B2 (en) 2017-04-04
KR102102087B1 (ko) 2020-04-20
US20170224785A1 (en) 2017-08-10
BR112015023542A8 (pt) 2019-12-03
JP2023071821A (ja) 2023-05-23
US10413600B2 (en) 2019-09-17
JP7238088B2 (ja) 2023-03-13
KR102218489B1 (ko) 2021-02-22
PT2968483T (pt) 2022-02-23
CA2905058A1 (en) 2014-09-25
NZ712440A (en) 2020-11-27
TW202313664A (zh) 2023-04-01
SG10201707074TA (en) 2017-10-30
AU2022211908A1 (en) 2022-09-01
IL290486B1 (en) 2023-04-01
JP2022027991A (ja) 2022-02-14
HK1220131A1 (zh) 2017-04-28
TW202138003A (zh) 2021-10-16
AU2013203062A1 (en) 2014-10-02
TWI786563B (zh) 2022-12-11
KR20190022926A (ko) 2019-03-06
IL241305B (en) 2020-04-30
KR20200041394A (ko) 2020-04-21
EA201591758A8 (ru) 2017-03-31
KR102365936B1 (ko) 2022-02-23
KR20220027266A (ko) 2022-03-07
EP2968483A1 (en) 2016-01-20
WO2014151968A8 (en) 2015-10-15
AU2016231547B2 (en) 2018-03-15
AU2016231547A1 (en) 2016-10-06
JP6998333B2 (ja) 2022-02-10
JP2016517421A (ja) 2016-06-16
EA034546B1 (ru) 2020-02-19
MX2015012783A (es) 2016-04-28
PL2968483T3 (pl) 2022-04-04
IL273365B (en) 2022-05-01
KR20210021107A (ko) 2021-02-24
CN114259558A (zh) 2022-04-01
US20220080032A1 (en) 2022-03-17
SG10202001227QA (en) 2020-03-30
AU2013203062B2 (en) 2016-06-23
US11185575B2 (en) 2021-11-30
AU2018203665A1 (en) 2018-06-14
JP2019142850A (ja) 2019-08-29
EP3960196A1 (en) 2022-03-02
NZ751610A (en) 2020-11-27
ES2906550T3 (es) 2022-04-19
IL273365A (en) 2020-05-31
EP2968483B1 (en) 2021-12-01
SG11201507271QA (en) 2015-10-29
AU2022211908B2 (en) 2023-11-30
CN105407912A (zh) 2016-03-16
BR112015023542A2 (pt) 2017-07-18
AU2020202738B2 (en) 2022-06-09
AU2018203665B2 (en) 2020-01-30
KR20160016756A (ko) 2016-02-15

Similar Documents

Publication Publication Date Title
JOP20200192A1 (ar) أجسام مضادة لـ tigit
EA201591758A1 (ru) Подкожное введение adamts13
GB2541571A (en) Pharmaceutical compositions
EA201690881A1 (ru) Соединения-ингибиторы аутотаксина
EA201690206A1 (ru) Терапевтически активные соединения и способы их применения
MX2014011134A (es) Compuestos de carbamato y preparacion y uso de los mismos.
PH12014501844A1 (en) Peptidomimetic macrocycles
MX2016000364A (es) Metodos para tratar o prevenir afecciones oftalmologicas.
EA201690513A1 (ru) Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний
TW201613636A (en) Methods of treating Alzheimer's Disease
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX2018005785A (es) Conjugados de anticuerpo anti-cd22-maytansina y metodos de uso de los mismos.
PH12017500602A1 (en) Methods for treating ocular conditions
MX2022006770A (es) Dispersiones solidas de bendamustina e infusion continua.
IN2013MU01985A (ru)
MX2019000677A (es) Células miméticas de células b.
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
PH12017501979A1 (en) Pharmaceutical compound
IN2014CH00035A (ru)
IN2014MU00077A (ru)
IN2013MU01510A (ru)

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG TJ TM

PC4A Registration of transfer of a eurasian patent by assignment